doi: 10.1002/cncr.34198
Some people simply dont tolerate incretin medications well despite trying multiple management strategies
CrossRef How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of RealWorld Observational Studies of GlucagonLike Peptide1 Receptor Agonists Zhengxuan Li, Yinan Huang, Hua Chen, Jieni Li Pharmacoepidemiology and Drug Safety .2026;[Epub] CrossRef Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Frontiers in Oncology .2026;[Epub] CrossRef Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai European Journal of Pharmacology .2025
Selenium helps to protect cells from oxidative stress and to support the normal functioning of the immune system
One of the biggest players is glucagon-like peptide-1, usually shortened to GLP-1
Take the First Step Towards a Healthier You Are you ready to experience the transformative power of The ReStart Shot
